Moderna Stock News

New Zealand High Court: Vaccine Mandate Not "Demonstrably Justified", Breach Of Rights Authored by Katabella Robert via The Epoch Times (emphasis ours), The New Zealand High Court has upheld a challenge to a vaccine mandate for Police and Defence Force staff, stating that it was not a “demonstrably justified” breach of the Bill of Rights. Police stop vehicles to heading north on state highway one at Warkworth in Auckland, New Zealand, on April 09, 2020. (Fiona Goodall/Getty Images) Justice Francis Cooke was asked by a group of Police and Defence Force personnel to judicially review the vaccine mandate enacted under the COVID-19 Public Health Response Act in December. The mandate required all Defence Force personnel and all Police constables, recruits, and authorized officers to receive two doses of the vaccine by March 1. But on Jan. 6, three unvaccinated staff who did not wish to receive the shots sought a judicial review of the mandate. They were supported by affidavits from 37 of their colleagues in the same position.

And this could lift one of investors'' biggest concerns.

A protein-based vaccine that GlaxoSmithKline and Sanofi hope to get approved has several advantages over mRNA-based vaccines made by companies like Moderna and Pfizer.

Growing Number Of Experts Call On US Govt To Recognize Natural Immunity Authored by Zachary Stieber via The Epoch Times, A growing number of experts are urging the U.S. government to formally recognize natural immunity , or the protection given by recovering from COVID-19 . More experts are arguing that the Centers for Disease Control and Prevention’s (CDC) recommended vaccination schedule should feature fewer doses—or none at all—for people who have contracted COVID-19 and survived. “Natural infection should count as two doses,” Dr. Paul Offit, professor of pediatrics at the Children’s Hospital of Philadelphia, and an adviser to the Food and Drug Administration on vaccines, told The Epoch Times. Offit and two former FDA officials stated in a recent op-ed that “requiring people who have been infected to get three shots is overkill at best—a waste of valuable doses—and an unnecessary risk at worst (given that vaccines have side effects, albeit rare ones).” Under current CDC guidance, all Americans 12 and older are advised to get three doses of the Moderna or Pfizer COVID-19 vaccines.

Watch Video European drugmakers Sanofi and Glaxosmithkline (GSK) released data showing their COVID vaccine is 100% effective at keeping patients out of the hospital. It has not been independently scientifically reviewed. Drugmakers Sanofi and GlaxoSmithKline have asked the Food and Drug Administration for emergency use authorization of their vaccine. "We are confident that this vaccine can play an important role as we continue to address this pandemic and prepare for the post-pandemic period," Roger Connor, president of GSK, said in a statement. Sanofi''s and GSK''s vaccine is based on a more conventional protein-based vaccine technology. It''s a recombinant protein vaccine, which means it recombines different segments of DNA. This uses DNA from the SARS-COV-2 spike protein, which COVID needs to enter and infect healthy cells. The combined DNA helps fire up your immune response. This is different from Pfizer and Moderna''s mRNA, or messenger RNA, technology. That vaccine uses a genetic code to teach the body''s cells how to make proteins that trigger immune responses.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Moderna has to focus on the rest of its pipeline to keep MRNA stock relevant and profitable as Covid vaccine revenues taper off by 2023. The post Moderna’s Covid Shot Alone Isn’t Enough to Revitalize a Sagging Stock appeared first on InvestorPlace . More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” Get in Now on Tiny $3 ‘Forever Battery’ Stock Interested in Crypto? Read This First…

Companies including Pfizer and Moderna so far have reported at least $79 billion in combined global sales of Covid-19 vaccines and treatments for 2021.

The Centers for Disease Control and Prevention said that younger males should consider waiting longer between doses of Pfizer Inc''s (NYSE: PFE ) / BioNTech SE (NASDAQ: BNTX ) and Moderna Inc''s (NASDAQ: MRNA ) COVID-19 vaccines to reduce a rare risk of heart inflammation. The CDC said males ages 12- to 39-years-old should consider waiting eight weeks between the first and second doses of their primary COVID-19 vaccination series,

Moderna has a new COVID-19 booster that combines the original vaccine with an Omicron-specifc one, Stéphane Bancel, Moderna CEO, said.

The advisory committee to European Union''s drug regulator on Friday said it has recommended reducing the interval between the second dose and booster dose of Moderna Inc''s COVID-19 vaccine from six months to three months.

In the fourth quarter of 2021, Moderna achieved a profit of $4.87 billion compared with a loss of $272 million in 2020. Total revenue increased from $571 million to $7.21 billion. In 2022, the company plans to further expand its commercial network by establishing or activating commercial subsidiaries.The U.S. biotech closed 2021 with a profit of $12.2 billion

After Thursday''s invasion of Ukraine, markets first sunk and then rose to close with all three major indexes posting gains for the day. Friday''s premarket was indicating a lower start again.

U.S. responds to Russia’s Ukraine invasion with more sanctions, Moderna sees fourth Covid-19 vaccine dose this fall, Morgan Stanley confirms federal probes of block-trading business, and other news to start your day.

https://www.investing.com/analysis/moderna-stock-could-test-resistance-200618759

Several days after world superpowers said they were close to signing a new Iranian nuclear deal, negotiators announced Thursday the talks would be put on hold due to the Russian… Read more » The post Iran Nuclear Talks on Hold Amid Russian Incursion appeared first on Hamodia . In related news: Al-Qaida Said to be Changing its Ways After Leaks U.K. Union to Push for Gov’t Rescue of British Steel Schools Close in French, German Virus Cluster Zones Head of China CDC Gets Injected With Experimental Vaccine Moderna Announces First Pediatric Phase 2/3 to Study Participants Dosed